EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Editas Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$2.42+0.07 (+2.98%)
Close on Oct 19, 2026
- Market cap
- $288.69M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.3%
120M of 154M shares
Institutional holders
215
35 new, 24 sold out
Net institutional buying
69M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $106.71K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daniel Schneeberger | 8,889,000 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Rajeev Shah | 8,889,000 | 5.80% | 13G (passive) | May 27, 2026 |
| Michael Kramarz | 16,045,802 | 9.90% | 13G (passive) | May 26, 2026 |
| Chen Yu | 15,798,999 | 9.90% | 13G (passive) | May 27, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EDIT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11,111,111 | 7.23% | $36.00M | New | 0.87% |
| BlackRock, Inc. | 10,589,990 | 6.90% | $34.31M | +1,326,678 | 0.00% |
| Commodore Capital LP | 8,889,000 | 5.79% | $28.80M | New | 1.72% |
| ADAR1 Capital Management, LLC | 8,889,000 | 5.79% | $28.80M | New | 1.32% |
| Ra Capital Management, L.P. | 8,889,000 | 5.79% | $28.80M | New | 0.25% |
| Vanguard Capital Management LLC | 6,141,336 | 4.00% | $19.90M | +1,936,967 | 0.00% |
| Paradigm Biocapital Advisors LP | 5,586,625 | 3.64% | $18.10M | New | 0.34% |
| Opaleye Management Inc. | 3,861,930 | 2.51% | $12.51M | +1,934,933 | 1.13% |
| Vanguard Portfolio Management LLC | 3,598,339 | 2.34% | $11.66M | +449,769 | 0.00% |
| Woodline Partners LP | 3,555,497 | 2.32% | $11.52M | New | 0.04% |
| Vivo Capital, LLC | 3,555,250 | 2.31% | $11.52M | New | 1.05% |
| GordonMD Global Investments LP | 3,127,000 | 2.04% | $10.13M | New | 4.90% |
| Goldman Sachs Group Inc | 2,614,036 | 1.70% | $8.47M | +2,055,459 | 0.00% |
| Geode Capital Management, LLC | 2,569,072 | 1.67% | $8.33M | +257,283 | 0.00% |
| Renaissance Technologies LLC | 2,468,919 | 1.61% | $8.00M | −1,503,241 | 0.01% |
| Logos Global Management LP | 2,222,000 | 1.45% | $7.20M | New | 0.31% |
| State Street Corp | 2,191,803 | 1.43% | $7.10M | +115,681 | 0.00% |
| Marshall Wace, Llp | 2,037,287 | 1.33% | $6.60M | +1,826,979 | 0.01% |
| D. E. Shaw & Co., Inc. | 1,901,002 | 1.24% | $6.16M | −42,891 | 0.00% |
| JPMorgan Chase & Co | 1,862,494 | 1.21% | $5.96M | −84,890 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 215 | 120M | 78.3% | 35 / 76 | 41 / 24 | 74M | 6M |
| Q1 2026 | 208 | 52M | 33.8% | 38 / 58 | 51 / 24 | 17M | 7M |
| Q4 2025 | 197 | 50M | 32.6% | 29 / 46 | 60 / 21 | 12M | 5M |
| Q3 2025 | 194 | 44M | 28.6% | 24 / 47 | 57 / 23 | 8M | 6M |
| Q2 2025 | 194 | 42M | 27.1% | 26 / 47 | 53 / 26 | 6M | 9M |
| Q1 2025 | 195 | 44M | 28.7% | 24 / 45 | 60 / 34 | 8M | 14M |
| Q4 2024 | 207 | 51M | 33.2% | 39 / 60 | 58 / 58 | 11M | 15M |
| Q3 2024 | 230 | 56M | 36.4% | 37 / 67 | 64 / 41 | 16M | 10M |
| Q2 2024 | 236 | 57M | 37.2% | 49 / 65 | 72 / 37 | 6M | 20M |
| Q1 2024 | 226 | 72M | 47.2% | 38 / 73 | 62 / 35 | 16M | 4M |
| Q4 2023 | 226 | 61M | 39.8% | 39 / 54 | 73 / 34 | 9M | 9M |
| Q3 2023 | 221 | 61M | 39.7% | 25 / 76 | 62 / 40 | 10M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EDIT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4,890,144 | 3.18% | $15.84M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,636,474 | 1.72% | $8.54M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,031,656 | 1.32% | $6.58M | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,100,306 | 0.72% | $3.56M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,091,084 | 0.71% | $2.81M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 844,017 | 0.55% | $2.73M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 687,467 | 0.45% | $2.23M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 509,394 | 0.33% | $1.76M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 505,306 | 0.33% | $1.75M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 476,309 | 0.31% | $1.65M | 0.01% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 415,301 | 0.27% | $1.35M | 0.04% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 336,592 | 0.22% | $1.09M | 0.07% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 291,435 | 0.19% | $1.01M | 0.01% | May 31, 2026 |
| JPMorgan Small Cap Value Fund | 278,861 | 0.18% | $903.51K | 0.07% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 278,830 | 0.18% | $903.41K | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO, Director | 243,189 | 0.16% | Sep 4, 2026 |
| Daniel Scott Ory | EVP, Chief Medical Officer | – | – | Sep 9, 2026 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 61,660 | 0.04% | Sep 4, 2026 |
| Amy Parison | SVP, Chief Financial Officer | 13,839 | 0.01% | Sep 4, 2026 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 112,720 | 0.07% | Mar 27, 2025 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 133,354 | 0.09% | Dec 5, 2024 |
| Patrick Thomas Ellinor II | Director | – | – | Aug 7, 2026 |
| Andrew Hirsch | Director | 2,000 | 0.00% | Jun 22, 2026 |
| David Scadden | Director | 0 | – | Jun 22, 2026 |
| Bernadette Connaughton | Director | 0 | – | Jun 22, 2026 |
| Elliott M. Levy | Director | – | – | Jun 22, 2026 |
| Jessica Hopfield | Director | 67,700 | 0.04% | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amy Parison SVP, Chief Financial Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −453 | $3.04 | $1.38K | 13,839 |
| Gilmore Neil O'Neill CEO, Director | Sep 3, 2026 | Sale(10b5-1 plan) | −5,124 | $3.04 | $15.58K | 243,189 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sep 3, 2026 | Sale(10b5-1 plan) | −709 | $3.04 | $2.16K | 61,660 |
| Amy Parison SVP, Chief Financial Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −678 | $2.58 | $1.75K | 14,292 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 28, 2026 | Sale(10b5-1 plan) | −4,928 | $2.67 | $13.16K | 62,369 |
| Amy Parison SVP, Chief Financial Officer | Jun 3, 2026 | Sale(10b5-1 plan) | −464 | $2.70 | $1.25K | 14,970 |
| Gilmore Neil O'Neill CEO, Director | Jun 3, 2026 | Sale(10b5-1 plan) | −15,380 | $2.70 | $41.53K | 248,313 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jun 3, 2026 | Sale(10b5-1 plan) | −731 | $2.70 | $1.97K | 67,297 |
| Amy Parison SVP, Chief Financial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −474 | $2.02 | $957 | 15,434 |
| Gilmore Neil O'Neill CEO, Director | Mar 3, 2026 | Sale(10b5-1 plan) | −5,394 | $2.02 | $10.90K | 263,693 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Sale(10b5-1 plan) | −749 | $2.02 | $1.51K | 68,028 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Dec 3, 2025 | Sale(10b5-1 plan) | −713 | $2.15 | $1.53K | 68,777 |
| Gilmore Neil O'Neill CEO, Director | Dec 3, 2025 | Sale(10b5-1 plan) | −5,603 | $2.15 | $12.05K | 269,087 |
| Amy Parison SVP, Chief Financial Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −461 | $2.15 | $991 | 15,908 |
| Amy Parison SVP, Chief Financial Officer | Sep 3, 2025 | Sale(10b5-1 plan) | −458 | $2.60 | $1.19K | 16,369 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Sep 3, 2025 | Sale(10b5-1 plan) | −710 | $2.60 | $1.85K | 69,490 |
| Gilmore Neil O'Neill CEO, Director | Sep 3, 2025 | Sale(10b5-1 plan) | −5,592 | $2.60 | $14.54K | 274,690 |
| Amy Parison SVP, Chief Financial Officer | Aug 7, 2025 | Sale(10b5-1 plan) | −679 | $2.58 | $1.75K | 16,827 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 31, 2025 | Sale(10b5-1 plan) | −5,121 | $2.49 | $12.75K | 64,398 |
| Amy Parison SVP, Chief Financial Officer | Jun 3, 2025 | Sale(10b5-1 plan) | −446 | $1.72 | $767 | 17,506 |
| Gilmore Neil O'Neill CEO, Director | Jun 3, 2025 | Sale(10b5-1 plan) | −15,192 | $1.72 | $26.13K | 280,282 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jun 3, 2025 | Sale(10b5-1 plan) | −726 | $1.72 | $1.25K | 69,519 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 4, 2025 | Sale(10b5-1 plan) | −2,891 | $1.71 | $4.94K | 70,245 |
| Gilmore Neil O'Neill CEO, Director | Mar 4, 2025 | Sale(10b5-1 plan) | −16,632 | $1.71 | $28.44K | 295,474 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 4, 2025 | Sale(10b5-1 plan) | −4,109 | $1.71 | $7.03K | 112,720 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Dec 3, 2024 | Sale(10b5-1 plan) | −541 | $2.08 | $1.13K | 133,354 |
| Gilmore Neil O'Neill CEO, Director | Dec 3, 2024 | Sale(10b5-1 plan) | −1,618 | $2.08 | $3.37K | 312,106 |
| Gilmore Neil O'Neill CEO, Director | Sep 4, 2024 | Sale(10b5-1 plan) | −1,555 | $3.42 | $5.32K | 313,724 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Sep 4, 2024 | Sale(10b5-1 plan) | −518 | $3.42 | $1.77K | 133,895 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 25, 2024 | Sale(10b5-1 plan) | −11,886 | $5.42 | $64.42K | 73,136 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Jul 19, 2024 | Sale(10b5-1 plan) | −6,619 | $5.21 | $34.48K | 134,413 |
| Gilmore Neil O'Neill CEO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −12,191 | $5.50 | $67.05K | 315,279 |
| Baisong Mei EVP, CHIEF MEDICAL OFFICER | Jun 4, 2024 | Sale(10b5-1 plan) | −511 | $5.50 | $2.81K | 141,032 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | May 20, 2024 | Sale(10b5-1 plan) | −22,337 | $5.61 | $125.31K | 116,829 |
| Jessica Hopfield Director | May 13, 2024 | Buy | +45,000 | $5.64 | $253.80K | 67,700 |
| Gilmore Neil O'Neill CEO, Director | Mar 5, 2024 | Sale(10b5-1 plan) | −77,824 | $9.42 | $733.10K | 327,470 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 4, 2024 | Sale(10b5-1 plan) | −20,327 | $9.42 | $191.48K | 141,543 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +19,458 | – | – | 142,413 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +19,457 | – | – | 161,870 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Mar 2, 2024 | Award | +50,900 | – | – | 122,955 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +130,700 | – | – | 260,869 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +72,213 | – | – | 333,082 |
| Gilmore Neil O'Neill CEO, Director | Mar 2, 2024 | Award | +72,212 | – | – | 405,294 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 2, 2024 | Award | +15,055 | – | – | 85,022 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Mar 2, 2024 | Award | +24,800 | – | – | 69,967 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 2, 2024 | Award | +25,966 | – | – | 139,166 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | Mar 2, 2024 | Award | +35,300 | – | – | 113,200 |
| Bruce Eaton EVP, CBO AND CTO | Dec 5, 2023 | Sale(10b5-1 plan) | −103 | $10.90 | $1.12K | 74,791 |
| Bruce Eaton EVP, CBO AND CTO | Nov 14, 2023 | Sale(10b5-1 plan) | −695 | $8.21 | $5.71K | 74,894 |
| Bruce Eaton EVP, CBO AND CTO | Nov 7, 2023 | Sale(10b5-1 plan) | −139 | $8.40 | $1.17K | 75,589 |
| Bruce Eaton EVP, CBO AND CTO | Sep 6, 2023 | Sale(10b5-1 plan) | −103 | $8.82 | $908 | 75,728 |
| Bruce Eaton EVP, CBO AND CTO | Aug 11, 2023 | Sale(10b5-1 plan) | −702 | $8.59 | $6.03K | 75,831 |
| Bruce Eaton EVP, CBO AND CTO | Aug 8, 2023 | Sale(10b5-1 plan) | −141 | $8.39 | $1.18K | 76,533 |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | Jul 24, 2023 | Award | +45,167 | – | – | 45,167 |
| Baisong Mei SVP, CHIEF MEDICAL OFFICER | Jul 19, 2023 | Sale(10b5-1 plan) | −4,317 | $8.80 | $37.99K | 72,055 |
| Gilmore Neil O'Neill CEO, Director | Jun 5, 2023 | Sale(10b5-1 plan) | −6,486 | $9.50 | $61.62K | 130,169 |
| Bruce Eaton EVP, CBO AND CTO | Jun 5, 2023 | Sale(10b5-1 plan) | −105 | $9.50 | $998 | 76,674 |
| Erick Lucera EVP, CHIEF FINANCIAL OFFICER | May 17, 2023 | Award | +77,900 | – | – | 77,900 |
| Michelle Robertson EVP, CHIEF FINANCIAL OFFICER | May 11, 2023 | Sale(10b5-1 plan) | −949 | $9.87 | $9.37K | 106,610 |
| Bruce Eaton EVP, CBO AND CTO | May 11, 2023 | Sale(10b5-1 plan) | −668 | $9.87 | $6.59K | 76,779 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Linda Burkly Officer | Aug 31, 2026 | 700 | $2.30K | Sep 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 31, 2026 | 5,100 | $16.73K | Sep 3, 2026 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Jul 21, 2026 | 5,500 | $15.84K | Jul 27, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | May 29, 2026 | 15,000 | $46.20K | Jun 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Feb 27, 2026 | 6,000 | $11.34K | Mar 3, 2026 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Dec 1, 2025 | 7,000 | $17.50K | Dec 3, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 29, 2025 | 7,000 | $19.11K | Sep 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Aug 29, 2025 | 800 | $2.18K | Sep 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Jul 30, 2025 | 7,500 | $25.95K | Jul 31, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Jun 2, 2025 | 20,000 | $37.40K | Jun 3, 2025 | Restricted Stock Unit Vesting |
| Linda Burkly Officer | Feb 28, 2025 | 6,000 | $11.16K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Erick Lucera Officer | Feb 28, 2025 | 8,000 | $14.88K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Feb 28, 2025 | 35,000 | $65.10K | Mar 3, 2025 | Restricted Stock Unit Vesting |
| Baisong Mei Officer | Aug 29, 2024 | 1,000 | $3.92K | Sep 3, 2024 | Restricted Stock Unit Vesting |
| Gilmore Neil O'Neill Officer, Director | Aug 29, 2024 | 3,000 | $11.76K | Sep 3, 2024 | Restricted Stock Unit Vesting |